Wesley Pharmaceuticals Launches 100 mg/mL NAD+ Injectables: What Providers Need to Know About the New 503B Offering

Table of Contents

  1. Key Highlights:
  2. Introduction
  3. Why NAD+ Matters: Cellular Biology and Clinical Interest
  4. What Wesley’s 100 mg/mL NAD+ Product Delivers
  5. Routes of Administration and Practical Clinical Uses
  6. Pairing NAD+ with Sermorelin and Weight-Management Protocols
  7. Regulatory Context: 503A vs 503B — What Providers Need to Know
  8. Quality, Packaging, and Supply-Chain Considerations
  9. Practical Guidance for Providers: Ordering, Eligibility, and Clinical Workflow
  10. Safety Profile, Contraindications, and Evidence Gaps
  11. Real-World Examples: How Clinics Are Using NAD+ Today
  12. Market Implications and the Competitive Landscape
  13. Liability, Documentation, and Payer Considerations
  14. Evaluating Evidence: What Clinicians Should Tell Patients
  15. The Future of NAD+ Therapies: Research and Commercial Trajectories
  16. FAQ

Key Highlights:

  • Wesley Pharmaceuticals is introducing a 100 mg/mL NAD+ injectable for IV, IM, and SubQ administration through its 503B outsourcing platform, expanding access to compounders and clinics that require office-use products.
  • The product ships in strengthened glass vials and is offered alongside complementary agents such as Sermorelin; availability is limited to providers in states where Wesley holds current 503B licensure (licensed in 29 states as of early 2026).
  • The launch reflects growing clinical and commercial interest in NAD+ for mitochondrial support, cognitive function, fatigue management, athletic recovery, and adjunctive anti-aging protocols, while underscoring regulatory, safety, and evidence considerations clinicians must weigh.

Introduction

Interest in targeted metabolic and longevity therapies has pushed clinics, wellness centers, and specialty pharmacies to broaden their offerings. Nicotinamide adenine dinucleotide (NAD+) sits at the center of that demand: a ubiquitous cellular cofactor tied to mitochondrial energy production, DNA repair, and several enzymatic pathways relevant to aging and recovery. Wesley Pharmaceuticals, the Orlando-based 503B outsourcing arm affiliated with Olympia Pharmaceuticals, has added a 100 mg/mL NAD+ injectable to its product lineup to meet clinician demand for a consistent, regulated source of compounded NAD+ suitable for intravenous, intramuscular, and subcutaneous administration.

The new offering raises practical questions for prescribers: how the formulation compares to existing NAD+ supplies, how to integrate it into treatment protocols, what regulatory obligations accompany 503B-sourced products, and what the clinical evidence and safety profile actually support. The remainder of this article examines the biology behind NAD+, the specifics of Wesley’s product, real-world clinical use cases, regulatory context for 503B compounding, and practical steps providers should take before incorporating NAD+ into practice.

Why NAD+ Matters: Cellular Biology and Clinical Interest

NAD+ is a central metabolic cofactor present in every living cell. It shuttles electrons between metabolic reactions, enabling mitochondria to convert nutrients into adenosine triphosphate (ATP), the immediate energy currency for cellular processes. NAD+ also participates in signaling pathways that regulate gene expression and is a substrate for enzymes involved in DNA repair and chromatin remodeling.

The clinical interest in NAD+ stems from two related observations. First, intracellular NAD+ concentrations decline with age and with certain chronic conditions, which correlates with reductions in mitochondrial efficiency, increased oxidative stress, and impaired cellular repair. Second, preclinical and early human studies suggest that restoring NAD+ levels can improve cellular bioenergetics, enhance repair mechanisms, and influence pathways implicated in metabolic health, neuroprotection, and tissue recovery. These features make NAD+ a logical target for clinicians focused on longevity medicine, fatigue syndromes, recovery after intensive training, and dermatologic or aesthetic outcomes tied to skin health.

Real-world practices reflect this scientific interest. IV therapy clinics and anti-aging centers commonly offer NAD+ infusions as part of comprehensive programs for cognitive enhancement, addiction recovery protocols, and athletic recovery regimens. While anecdotal reports frequently highlight benefits such as improved mental clarity, reduced brain fog, and increased stamina, controlled evidence varies by indication and formulation. For prescribers, the distinction between biological plausibility and robust clinical proof matters when counseling patients and documenting medical necessity.

What Wesley’s 100 mg/mL NAD+ Product Delivers

Wesley’s new NAD+ injectable is supplied at a concentration of 100 mg/mL and designed for administration by IV, IM, or SubQ injection. The product's packaging and vial construction emphasize clinical use: vials are made from advanced glass intended to reduce breakage and improve shelf-handling in busy office settings. These physical enhancements may reduce replacement costs and support safer handling during preparation and administration.

Key practical features clinicians will want to confirm:

  • Concentration and volume options: 100 mg/mL permits flexible dosing protocols. Providers should confirm available vial sizes and total NAD+ per vial to plan dosing and calculate costs.
  • Routes of administration: The formulation supports IV infusions, intramuscular injections, and subcutaneous injections, enabling practices with differing capabilities to employ the product.
  • Compatibility and co-formulations: Wesley markets NAD+ for use in combination with agents such as Sermorelin. While combination kits exist for weight-management programs, clinicians must evaluate compatibility and stability when mixing agents and follow local compounding laws and guidance.
  • Regulatory compliance: As a 503B-sourced product, Wesley’s NAD+ is manufactured under outsourcing facility standards and distributed for office use where permitted by state law and facility licensure.

These attributes aim to provide clinicians with a ready-to-use, consistent NAD+ supply that reduces the preparation burden on individual practices and aligns with regulatory expectations for office-use compounded products.

Routes of Administration and Practical Clinical Uses

NAD+ administration varies across clinical settings. IV infusions deliver the compound directly into the bloodstream, enabling higher systemic exposure over a controllable infusion period. IM injections allow for depot-like absorption into muscle tissue, and SubQ injections are convenient for smaller-volume, outpatient administration.

Common clinical objectives associated with NAD+ dosing include:

  • Cognitive and neurocognitive support: Clinics report improvements in attention, mental clarity, and mood among certain patients following NAD+ infusions. Protocols vary from single-dose interventions to multi-day regimens depending on goals.
  • Fatigue and chronic fatigue syndromes: Patients with persistent fatigue may be trialed on NAD+-based regimens when other metabolic contributors have been evaluated.
  • Athletic recovery and performance: Some sports medicine providers incorporate NAD+ into post-exertion recovery protocols, aiming to accelerate metabolic recovery and reduce perceived fatigue.
  • Skin quality and aesthetic adjuncts: NAD+ plays roles in DNA repair and cellular turnover, which has encouraged its inclusion in dermatologic and aesthetic treatment plans where skin tone and texture are priorities.
  • Addiction recovery: NAD+ treatments have been used in some addiction clinics, though rigorous evidence remains limited; protocols there often prioritize supportive care and close monitoring.

Real-world protocols reflect substantial variability. For example, NAD+ infusion schedules reported across clinics range from high-dose multi-hour infusions delivered daily over a series of days for more intensive "reset" approaches, to lower-dose, intermittent maintenance infusions administered weekly or monthly. The 100 mg/mL concentration gives clinicians flexibility to tailor infusion volumes and rates to individual patient needs.

Clinicians must evaluate each patient comprehensively before initiating NAD+ therapy: obtain a detailed medical history, review current medications (to avoid interactions), confirm intravenous access and monitoring protocols, and discuss realistic expectations based on current evidence.

Pairing NAD+ with Sermorelin and Weight-Management Protocols

Wesley’s NAD+ is being offered alongside Sermorelin, a synthetic analog of growth hormone–releasing hormone (GHRH). Clinicians often combine agents when their mechanisms may be complementary: NAD+ targets cellular bioenergetics and repair processes at the mitochondrial and enzymatic level, while Sermorelin stimulates pulsatile growth hormone release, which can affect lean mass, metabolic rate, and sleep architecture.

Typical applications for combining NAD+ and Sermorelin include:

  • Weight-management regimens that pair metabolic support with hormonal optimization to support fat loss and preserve lean body mass during calorie restriction.
  • Comprehensive anti-aging programs where both cellular energy support and endocrine modulation are part of a broader strategy to address age-associated declines in function.
  • Athletic programs that emphasize recovery and anabolic support.

When prescribing combinations, clinicians must ensure:

  • Legal and regulatory compliance: 503B-sourced NAD+ may be paired with prescription-only agents under certain circumstances but local laws and payer requirements differ.
  • Safety monitoring: Co-administration of agents that affect metabolism or endocrine function requires baseline and follow-up labs to monitor glucose, lipid profiles, hormone levels, and adverse effects.
  • Evidence-based expectations: While biologically plausible, additive clinical benefits for combined regimens are not guaranteed and should be discussed candidly with patients.

Some weight-management clinics have integrated Sermorelin into standardized kits that include lifestyle coaching and nutritional support. Pairing NAD+ with such kits can create a comprehensive offering, but outcomes hinge on patient selection, adherence, and multimodal care.

Regulatory Context: 503A vs 503B — What Providers Need to Know

Compounded medications enter the market through two primary pathways: 503A compounding pharmacies and 503B outsourcing facilities. The distinction has material implications for practitioners purchasing NAD+ or other compounded products.

  • 503A pharmacies produce patient-specific compounded prescriptions and generally require a practitioner-patient-pharmacist relationship. These products are often dispensed directly to the patient for self-administration or use in-office under a prescription.
  • 503B outsourcing facilities manufacture compounded drugs at scale for office use without a patient-specific prescription, but they must register with the FDA, comply with current Good Manufacturing Practices (cGMP), and are subject to FDA inspections and oversight.

Wesley operates as a 503B outsourcing facility, which means its products are intended to supply healthcare providers and clinics with compounded medications for office use where state law permits. Benefits of sourcing from a 503B provider include standardized manufacturing processes, batch testing, quality control documentation, and often improved supply reliability compared with small-scale compounding pharmacies. For practices that lack the capacity to compound in-house or that prefer to source ready-to-use products with associated quality documentation, 503B suppliers can reduce logistical burdens and regulatory risk.

However, providers must confirm:

  • State licensure and distribution rules: Wesley maintains licensure in a subset of states (29 states as of early 2026). Providers in non-licensed states cannot receive distribution for office use until licensure is established there.
  • Required paperwork: Facilities must submit updated 503B-related documentation to receive product shipments.
  • Limitations on patient-specific prescriptions: 503B products are generally for office-use and are not intended to replace patient-specific 503A compounded prescriptions in jurisdictions or clinical scenarios that require individualized compounding.

Understanding these differences ensures legal compliance and protects patient safety.

Quality, Packaging, and Supply-Chain Considerations

Wesley emphasized durable glass vials and enhanced packaging for clinical accessibility. For practices that administer IV or injectable agents frequently, packaging resilience reduces breakage risk and improves inventory management. Beyond physical attributes, clinicians should review the supplier’s quality assurance practices:

  • Batch testing and certificate of analysis (CoA): Reliable 503B facilities provide CoAs that document identity, potency, purity, and absence of microbial contamination for each lot.
  • Stability and storage guidance: NAD+ stability varies by formulation, concentration, and storage conditions. Providers should confirm recommended storage temperatures, beyond-use dates after opening, and any requirements for light protection.
  • Supply continuity: Clinics that incorporate NAD+ into regular service offerings require predictable supply. Outsourcing facilities with scalable production and distribution networks typically offer greater continuity than smaller pharmacies.
  • Traceability and recall procedures: Providers should understand how the outsourcing facility handles adverse events, lot tracking, and recalls to enable rapid responses if issues arise.

These considerations reduce clinical disruption and support compliance with state pharmacy board expectations.

Practical Guidance for Providers: Ordering, Eligibility, and Clinical Workflow

If a practice is considering adding Wesley’s NAD+ product, the steps below outline practical actions and workflow integration points.

  1. Confirm eligibility and licensure: Check Wesley’s license tracker to verify distribution to your state and ensure your office has submitted required 503B paperwork. If located in an unlicensed state, discuss alternatives with a pharmacist or consider patient-specific 503A prescriptions.
  2. Establish an account: Open an account with Olympia/Wesley via the provider contact portal and request product specifications, CoAs, and material safety data.
  3. Review product documentation: Obtain the lot-specific CoA, batch release documentation, and recommended administration guidance from the manufacturer.
  4. Choose dosing protocols: Develop written treatment protocols tailored to patient populations (e.g., fatigue, recovery, cognitive support). Include baseline assessments, such as metabolic panels, liver function tests, and relevant hormonal evaluations when combining with agents like Sermorelin.
  5. Train staff: Ensure nursing and pharmacy personnel understand preparation, infusion rates, monitoring parameters, and emergency responses for adverse reactions during IV administration.
  6. Consent and documentation: Implement informed consent forms that describe potential benefits, known risks, and the experimental nature of some NAD+ applications. Maintain thorough clinical notes and outcome tracking.
  7. Monitor outcomes and safety: Use objective measures where possible—cognitive screens, fatigue scales, performance metrics, or lab markers—to assess response and justify ongoing therapy.
  8. Inventory and storage: Follow product storage instructions, track beyond-use dates after vial puncture, and implement standard operating procedures for aseptic handling.

These steps align clinical practice with regulatory and safety expectations and help practices make informed decisions about service offerings.

Safety Profile, Contraindications, and Evidence Gaps

NAD+ is generally well-tolerated when administered appropriately, but clinicians must respect its pharmacologic activity and monitor patients. Reported adverse reactions include infusion-related reactions (nausea, flushing, dizziness), local injection-site discomfort, and rare allergic responses. Because NAD+ participates in many enzymatic pathways, theoretical concerns include interactions with concurrent medications and effects on metabolic regulation.

Key safety and evidence considerations:

  • Baseline screening: Evaluate for cardiac conditions, uncontrolled hypertension, or severe metabolic derangements that may complicate IV therapy.
  • Drug interactions: While NAD+ itself is not commonly linked to direct interactions, the metabolic and hormonal milieu can shift in response to therapy. Providers should review medications that affect mitochondrial function or metabolic pathways.
  • Pregnant and lactating patients: Data are limited; many clinics exclude these populations or require careful risk–benefit discussion.
  • Long-term outcomes: High-quality, long-term randomized trials in humans remain limited for many of the claimed indications. While mechanistic and early-phase human studies underpin clinical enthusiasm, robust evidence for disease modification or durable functional improvements is still evolving.
  • Special populations: Patients with autoimmune disease, advanced hepatic disease, or active malignancy require individualized risk assessment.

Clinicians should disclose the current state of evidence to patients and document the rationale for therapy. When outcomes are uncertain, conservative dosing, close monitoring, and shared decision-making are prudent.

Real-World Examples: How Clinics Are Using NAD+ Today

Across the United States and internationally, practices have adapted NAD+ therapy to different clinical contexts. Representative use-cases illustrate the spectrum of application:

  • A metropolitan IV therapy center offers a "cognitive clarity" package: an initial four-hour infusion course followed by monthly maintenance infusions. Patients are screened for thyroid and metabolic issues, and outcomes are tracked using cognitive symptom questionnaires.
  • A sports medicine clinic integrates NAD+ into post-season recovery programs for collegiate athletes, pairing treatments with nutritional support, sleep optimization, and graded exercise rehabilitation.
  • A weight-loss clinic uses a kit that combines Sermorelin, NAD+, and lifestyle counseling for patients with metabolic slowdown after multiple unsuccessful diet attempts. The clinic requires baseline endocrine panels and monitors body composition changes over a 12-week program.
  • An addiction clinic uses short NAD+ infusion series as adjunctive therapy during medically supervised withdrawal, noting anecdotal reductions in cravings and improved energy levels, while maintaining psychosocial and pharmacologic supports as standard of care.

These examples show adaptability but also underscore the need for standardized outcome measures and controlled studies to quantify benefit across populations.

Market Implications and the Competitive Landscape

Wesley’s NAD+ launch signals stronger commercialization of niche metabolic therapies within regulated compounding. As demand grows, several market forces will shape availability and practice uptake:

  • Regulatory enforcement: The 503B pathway demands cGMP compliance, which favors larger players capable of investing in manufacturing infrastructure and quality programs. Smaller clinics and compounding pharmacies may struggle to match these standards.
  • Consolidation: Larger healthcare networks and national wellness brands may prefer established outsourcing suppliers to ensure product consistency and legal defensibility.
  • Product differentiation: Features such as vial design, stability data, and bundling with complementary agents (e.g., Sermorelin) will influence purchasing decisions.
  • Evidence development: Sponsors and providers may collaborate on formal registries or investigator-initiated studies to gather real-world data. Such efforts could inform dosing, safety, and efficacy for specific indications.
  • Geographic expansion: Wesley’s staged licensure across states will affect market penetration. As the company secures additional state authorizations, supply options for providers will broaden.

Clinics evaluating investments in NAD+ services should weigh upfront costs, staff training, expected patient demand, and the evolving reimbursement environment. For many providers, consistent access to a regulated, quality-assured product reduces administrative overhead and legal exposure compared with informal sourcing.

Liability, Documentation, and Payer Considerations

When offering compounded injectables for office use, practices must manage clinical, legal, and billing dimensions:

  • Documentation: Thorough clinical documentation, including indication, consent, contraindication assessments, and monitoring notes, helps demonstrate medical necessity and supports risk management.
  • Billing: NAD+ infusions are often cash-pay services within wellness and aesthetic practices. Insurance coverage is typically limited except when a clear, accepted medical indication exists. Clear pricing, refund policies, and patient communication are essential to avoid disputes.
  • Malpractice and product liability: Using products from 503B facilities generally reduces compounding-related liability risks due to the supplier’s compliance with higher manufacturing standards. Nevertheless, practices retain responsibility for safe administration and appropriate patient selection.
  • Adverse events reporting: Practices should have protocols for reporting significant adverse events to the supplier and relevant authorities, and for internal root-cause analysis when administration errors occur.

These operational considerations protect clinics and support safer patient care.

Evaluating Evidence: What Clinicians Should Tell Patients

Patients seeking NAD+ frequently come with high expectations, driven by marketing, testimonials, and a desire for quick improvements in energy or cognition. Clinicians must provide balanced information:

  • Explain mechanisms: Describe how NAD+ supports mitochondrial function and DNA repair in accessible terms.
  • Clarify evidence levels: Distinguish between preclinical rationale, case series, and randomized controlled trials. For many applications—particularly subjective outcomes like fatigue and cognitive function—evidence is mixed and limited by small sample sizes or inconsistent dosing regimens.
  • Set realistic goals: Offer measurable targets for therapy (e.g., improved sleep scores, reduction in fatigue scale, enhanced training recovery) and define timeframes for reassessment.
  • Emphasize multimodal care: Position NAD+ as one component rather than a standalone cure. Lifestyle interventions—sleep, nutrition, exercise, and management of comorbid conditions—remain foundational to durable outcomes.
  • Offer follow-up plans: Set intervals for lab monitoring, symptom reassessment, and discussion of whether to continue or modify therapy based on objective and subjective response.

Transparent counseling supports ethical practice and avoids unrealistic promises that can undermine trust.

The Future of NAD+ Therapies: Research and Commercial Trajectories

The expansion of regulated NAD+ supply through 503B channels is likely to accelerate clinical use and stimulate research. Areas where data are needed include:

  • Dose-response relationships: Determining optimal dosing strategies for different indications and administration routes.
  • Long-term safety: Characterizing effects of repeated or chronic NAD+ therapy on metabolic and endocrine systems.
  • Comparative effectiveness: How NAD+ compares with alternative metabolic modulators or nutritional strategies.
  • Biomarker development: Identifying reliable surrogate markers to track biological response to therapy and guide personalized dosing.

Commercially, partnerships between clinical networks, outsourcing facilities, and researchers could produce registries and pragmatic trials that enhance the evidence base. As such data mature, payer coverage decisions and standard-of-care recommendations may evolve.

FAQ

Q: What is the concentration and intended administration of Wesley’s NAD+ product? A: Wesley’s NAD+ is supplied at 100 mg/mL and is formulated for IV infusions as well as intramuscular and subcutaneous injections, allowing clinicians to choose the route that best fits clinical goals and practice capabilities.

Q: How does sourcing NAD+ from a 503B outsourcing facility differ from a 503A compounding pharmacy? A: 503B outsourcing facilities manufacture office-use compounded drugs under cGMP and FDA oversight, providing batch testing and quality assurance suitable for distribution to clinics. 503A pharmacies compound patient-specific prescriptions and operate under different regulatory frameworks. Providers should confirm which pathway is required or preferred for their jurisdiction and clinical application.

Q: Which states can receive Wesley’s NAD+ product? A: Wesley was licensed in 29 states as of early 2026. Providers should consult Wesley’s license tracker and complete required 503B documentation to confirm eligibility in their state.

Q: Can Wesley’s NAD+ be combined with other agents like Sermorelin? A: Wesley markets combinations and kits that pair NAD+ with agents such as Sermorelin for weight-management and metabolic protocols. Clinicians must ensure compatibility, follow stability guidance, and meet regulatory requirements for co-administered agents.

Q: What evidence supports NAD+ for cognitive function, fatigue, or athletic recovery? A: Biological mechanisms support the potential of NAD+ to enhance mitochondrial function and cellular repair. Clinical evidence includes early-phase trials, case series, and anecdotal reports indicating possible benefits for cognition, fatigue, and recovery. Large, well-controlled trials for many specific indications are still limited.

Q: What are the main safety concerns and contraindications? A: Reported adverse effects include infusion-related symptoms (nausea, lightheadedness), local injection-site discomfort, and allergic reactions in rare cases. Patients with significant cardiac disease, unstable metabolic conditions, or active malignancy require cautious evaluation. Pregnancy and lactation lack robust safety data and are often treated as exclusions.

Q: How should clinics integrate NAD+ into practice workflows? A: Confirm state eligibility, establish an account with the supplier, obtain CoAs and stability data, develop written protocols, train nursing and pharmacy staff, obtain informed consent, and implement monitoring and documentation systems. Start with conservative dosing for new indications and track objective outcomes.

Q: Is NAD+ typically covered by insurance? A: Most NAD+ infusions and wellness-oriented protocols are cash-pay. Insurance coverage may be possible for specific medical indications with supporting documentation, but practices should verify payer policies and establish clear billing communication with patients.

Q: What should providers ask from Wesley before purchasing? A: Request lot-specific CoAs, stability and storage recommendations, administration guidance, vial sizes and total NAD+ per vial, and details on state licensure and distribution policies. Also clarify procedures for adverse-event reporting and recall notifications.

Q: What are realistic patient expectations after NAD+ therapy? A: Some patients report improvements in energy, mental clarity, and recovery, often within days to weeks. Responses vary, and durable functional improvements typically rely on adjunctive lifestyle measures and management of underlying conditions. Set measurable goals and schedule reassessments to guide ongoing therapy.

Wesley Pharmaceuticals’ introduction of a 100 mg/mL NAD+ injectable through a 503B pathway offers clinicians a regulated source for a compound frequently used in metabolic, recovery, and longevity-focused care. Providers should balance enthusiasm with careful patient selection, rigorous documentation, and a commitment to monitoring outcomes. As regulatory footprints expand and evidence accrues, NAD+ may find clearer roles across discrete clinical niches. For now, practical preparation and transparent communication with patients remain essential.